Ad Comm gives thumbs up to The Medicines Company's cangrelor

• The FDA's Cardiovascular and Renal Drugs Advisory Committee votes 9 -2 (1 abstain) in favor of approval of The Medicines Company's (MDCO) cangrelor as an adjunct to percutaneous coronary intervention (PCI) for reducing the risks of thrombotic events associated with PCI and 7 - 2 in favor of cangrelor in certain patients undergoing angioplasty.
• Previously: Ad Comm approaches for The Medicines Company's cangrelor NDA; Resubmitted data supports approval (April 13)